Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA.
Ebara S, Yoshida M, Yamakawa H, Shimokawa K, Inoue Y, Tauchi H, Morishita D.

CDK12 is a promising therapeutic target for the transcription cycle and DNA damage response in metastatic osteosarcoma.
Li Z, Li X, Seebacher NA, Liu X, Wu W, Yu S, Hornicek FJ, Huang C, Duan Z.

Structure-independent machine-learning predictions of the CDK12 interactome.
Karolak A, Urbaniak K, Monastyrskyi A, Duckett DR, Branciamore S, Stewart PA.,

Tubule-specific cyclin-dependent kinase 12 knockdown potentiates kidney injury through transcriptional elongation defects.
Zhang YL, Tang TT, Ni WJ, Li ZT, Jiang LY, Wang Y, Zhou X, Cao JY, Yin Q, Jiang W, Zhao YJ, Gan WH, Zhang AQ, Li ZL, Wen Y, Lv LL, Liu BC, Wang B., Free PMC Article

Cyclin-dependent kinase 12 deficiency reprogrammes cellular metabolism to alleviate ferroptosis potential and promote the progression of castration-resistant prostate cancer.
Zhang H, Zhou Y, Feng Y, Hou W, Chen Y, Xing Z, Zhang Y, Wei Q, Yin Y, Guo J, Hu H., Free PMC Article

Analysis of Breast Cancer Brain Metastases Reveals an Enrichment of Cyclin-Dependent Kinase 12 Structural Rearrangements in Human Epidermal Growth Factor Receptor 2-Positive Disease.
Bhogal T, Giannoudis A, Sokol E, Ali S, Palmieri C.

ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features.
Forster-Sack M, Zoche M, Pestalozzi B, Witzel I, Schwarz EI, Herzig JJ, Fansa H, Tausch C, Ross J, Moch H, Varga Z., Free PMC Article

Trans-Regulation of Alternative PD-L1 mRNA Processing by CDK12 in Non-Small-Cell Lung Cancer Cells.
Larsen TV, Maansson CT, Daugaard TF, Andresen BS, Sorensen BS, Nielsen AL., Free PMC Article

Inhibition of CDK12 elevates cancer cell dependence on P-TEFb by stimulation of RNA polymerase II pause release.
Wang Z, Himanen SV, Haikala HM, Friedel CC, Vihervaara A, Barborič M., Free PMC Article

CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway.
Gao LZ, Wang JQ, Chen JL, Zhang XL, Zhang MM, Wang SL, Zhao C.

CDK12 loss inhibits cell proliferation by regulating TBK1 in non-small cell lung cancer cells.
Liu X, Liu Y, Chai W, Yan M, Li H, Li J, Sun L, Cao Y, Liu Q, Sun Y, Pan H.

CDK12 alterations and ARID1A mutations are predictors of poor prognosis and therapeutic targets in high-grade salivary gland carcinoma: analysis of the National Genomic Profiling Database.
Kobayashi K, Saito Y, Kage H, Fukuoka O, Yamamura K, Mukai T, Oda K, Yamasoba T.

Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
Jang A, Lanka SM, Huang M, Casado CV, Caputo SA, Sweeney PL, Gupta K, Pocha O, Habibian N, Hawkins ME, Lieberman AD, Schwartz J, Jaeger EB, Miller PJ, Layton JL, Barata PC, Lewis BE, Ledet EM, Sartor O.

CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1.
Panzeri V, Pieraccioli M, Cesari E, de la Grange P, Sette C., Free PMC Article

CDK12 and Integrator-PP2A complex modulates LEO1 phosphorylation for processive transcription elongation.
Qiu M, Yin Z, Wang H, Lei L, Li C, Cui Y, Dai R, Yang P, Xiang Y, Li Q, Lv J, Hu Z, Chen M, Zhou HB, Fang P, Xiao R, Liang K., Free PMC Article

Prognostic and clinicopathological value of CDK12 mutation in prostate cancer: a meta-analysis.
Zhang W, Zhou L, Di J.

CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma.
Houles T, Lavoie G, Nourreddine S, Cheung W, Vaillancourt-Jean É, Guérin CM, Bouttier M, Grondin B, Lin S, Saba-El-Leil MK, Angers S, Meloche S, Roux PP., Free PMC Article

CDK12 orchestrates super-enhancer-associated CCDC137 transcription to direct hepatic metastasis in colorectal cancer.
Dai W, Wu J, Peng X, Hou W, Huang H, Cheng Q, Liu Z, Luyten W, Schoofs L, Zhou J, Liu S., Free PMC Article

CDK12 activates MYC to repress miR-28-5p/EZH2 and amplifies tonic BCR signaling to promote the development of diffuse large B-cell lymphoma.
Liu QH, Dai GR, Wang XN, Wang L, Li LL, Wu ZS, Xia RX.

Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Gao J, Wang MY, Ren Y, Lwin T, Li T, Yan JC, Sotomayor EM, Duckett DR, Shah BD, Shain KH, Zhao X, Tao J., Free PMC Article

CDK12 Is Necessary to Promote Epidermal Differentiation Through Transcription Elongation.
Li J, Tiwari M, Chen Y, Luanpitpong S, Sen GL., Free PMC Article

Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.
Elliott A, Zhang J, Zhang Q, Swensen J, Martin D, Xiu J, Geynisman DM, Vaena D, Herzog TJ, Holloway RW, El-Deiry WS, Spetzler D, Heath E, Stafford P, Korn WM.

SMG1 and CDK12 Link ΔNp63α Phosphorylation to RNA Surveillance in Keratinocytes.
Bamberger C, Pankow S, Yates JR 3rd., Free PMC Article

Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer.
Dieter SM, Siegl C, Codó PL, Huerta M, Ostermann-Parucha AL, Schulz E, Zowada MK, Martin S, Laaber K, Nowrouzi A, Blatter M, Kreth S, Westermann F, Benner A, Uhrig U, Putzker K, Lewis J, Haegebarth A, Mumberg D, Holton SJ, Weiske J, Toepper LM, Scheib U, Siemeister G, Ball CR, Kuster B, Stoehr G, Hahne H, Johannes S, Lange M, Herbst F, Glimm H.

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.
Warner E, Herberts C, Fu S, Yip S, Wong A, Wang G, Ritch E, Murtha AJ, Vandekerkhove G, Fonseca NM, Angeles A, Beigi A, Schönlau E, Beja K, Annala M, Khalaf D, Chi KN, Wyatt AW.